|Articles|December 20, 2001

CDER Drug Approvals

Author(s)BioPharm International Editors

Drug Approvals [Includes Drug Label and Approval Letter] (Updated 12/18/2001)

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential

ByFeliza Mirasol

October 27th 2025

Welcome to CPHI Frankfurt 2025

BySusan Haigney

October 27th 2025

BioPharm Weekly News Roundup—Week of Oct. 20, 2025

ByFeliza Mirasol

October 24th 2025

Antibodies, immunoglobulin Ig proteins 3D medical background. Immune system, IgM, IgG, IgE, IgD, IgA antibodies glycoproteins, specific antigens against coronavirus sars-cov-2 covid-19 influenza virus | Image credit: © Corona Borealis - © Corona Borealis - stock.adobe.com

Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances

ByFeliza Mirasol

October 24th 2025

Colorful 3D glass molecules and atoms in blue background. | Image credit: © Drawbot - © Drawbot - stock.adobe.com

SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks

ByFeliza Mirasol

October 23rd 2025

CDER Drug Approvals

Newsletter

Related Content

Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential

Welcome to CPHI Frankfurt 2025

BioPharm Weekly News Roundup—Week of Oct. 20, 2025

Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances

SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks

Trending on BioPharm International

Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential

Welcome to CPHI Frankfurt 2025

Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics